|1.||Chauhan, Subhash C: 4 articles (06/2015 - 01/2013)|
|2.||Jaggi, Meena: 4 articles (06/2015 - 01/2013)|
|3.||Singh, Man Mohan: 3 articles (06/2015 - 06/2009)|
|4.||Ebeling, Mara C: 3 articles (06/2015 - 01/2015)|
|5.||Khan, Sheema: 3 articles (06/2015 - 01/2015)|
|6.||Singh, M M: 3 articles (08/2006 - 06/2004)|
|7.||Thompson, Paul A: 2 articles (06/2015 - 01/2015)|
|8.||Zafar, Nadeem: 2 articles (06/2015 - 01/2015)|
|9.||Chauhan, Neeraj: 2 articles (06/2015 - 01/2015)|
|10.||Yallapu, Murali M: 2 articles (06/2015 - 01/2015)|
11/01/2013 - "This study was carried out to evaluate the efficacy of Ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. "
11/01/2013 - "A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding."
11/01/2013 - "The results in this study indicate that Ormeloxifene, a non-steroidal, non-hormonal agent, provides effective and favourable pharmacological management option with least side effects, suitable for the treatment of dysfunctional uterine bleeding."
01/01/2013 - "Ormeloxifene can be used asa effective drug in the treatment of Dysfunctional uterine bleeding."
03/01/2013 - "Ormeloxifene showed significant efficacy for treating breast pain and nodularity."
03/01/2013 - "A randomized, double-blind, placebo-controlled trial of ormeloxifene in breast pain and nodularity."
03/01/2013 - "We did a randomized, double-blind, placebocontrolled trial of oral ormeloxifene 30 mg, a selective oestrogen receptor modulator (SERM) or placebo twice a week for 3 months in 20-50-year-old women with breast pain with or without lumpiness. "
08/01/2009 - "Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia."
08/01/2009 - "Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study."
08/01/2009 - "To assess the efficacy and safety of ormeloxifene (centchroman) in the medical management of menorrhagia. "
10/01/1997 - "The present study was undertaken to investigate the effect of the L-enantiomer (levormeloxifene) and the d-enantiomer (d-ormeloxifene) on the development of atherosclerosis. "
10/01/1997 - "In the long-term experiment, levormeloxifene, in contrast to d-ormeloxifene, significantly reduced atherosclerosis by 50% in the undamaged arterial wall of both female and male rabbits. "
06/01/2015 - "Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. "
01/01/2015 - "Ormeloxifene (ORM), a synthetic molecule, has exhibited potent anti-cancer effects through inhibition of important oncogenic and proliferation signaling pathways. "
01/01/2013 - "The current review summarizes recent findings on ormeloxifene as an anti-cancer agent and future prospects of this clinically safe pharmacophore. "
01/01/2013 - "For these reasons and to circumvent these obstacles, ormeloxifene is a promising candidate on a fast track for the development or repurposing established drugs as anti-cancer agents for cancer treatment. "
06/01/2015 - "In addition, invasiveness of tumor cells cocultivated with TGFβ-stimulated human pancreatic stromal cells was effectively inhibited by ormeloxifene treatment alone or in combination with gemcitabine. "
|1.||Selective Estrogen Receptor Modulators (SERM)
|5.||Macrophage Colony-Stimulating Factor
|6.||Biological Markers (Surrogate Marker)
|7.||Ornithine Decarboxylase (Decarboxylase, Ornithine)
|10.||DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
|2.||Contraception (Birth Control)
|3.||Heterologous Transplantation (Xenotransplantation)